Bristol Myers Squibb Reports First Quarter Financial Results

Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile



First Quarter Revenues were $11.9 Billion, increasing 5%


Growth Portfolio Revenues were $4.8...

Related Keywords

Puerto Rico , United States , Bristol Myers Squibb , Christopher Boerner , Pomalyst Imnovid , Exchange Commission , Karuna Therapeutics Inc , European Commission , European Union , International Intl , Facebook , Mirati Therapeutics Inc , Twitter , Business Development , Instagram , B Drug Pricing Program , European Medicines Agency , Linkedin , Youtube , Securities Exchange , Drug Administration , Clinical Research , Rayzebio Inc , Bristol Myers , Earnings Per Share , Licensing Income Net Impact , Karuna Therapeutics , Myers Squibb , Mirati Therapeutics , Ended March , Legacy Portfolio , New Drug Application , Priority Review , Prescription Drug User Fee Act , Biologics Application , Blinded Independent Central Review , Enhancing Productivity , Statement Regarding Forward Looking , Accepted Accounting Principles , Nimbus Therapeutics , Securities Act , Securities Exchange Act , Drug Pricing Program , Annual Report , Quarterly Reports , Current Reports , Months Ended March , Earnings Before Income Taxes , Income Taxes , Earnings Attributable , Average Common Shares Outstanding , Common Share , Specified Items , Markets ,